HC Wainwright & Co. Reiterates Buy on First Tracks, Maintains $57 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates First Tracks (NASDAQ:TRAX) with a Buy and maintains $57 price target.
Stocks · News reference
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
TRAX reported narrower Q2 loss of 95 cents per share. Analysts raised price targets for the stock, citing potential for ANB033 in immune diseases.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
Barclays Maintains Overweight on First Tracks, Raises Price Target to $65
Barclays analyst Etzer Darout maintains First Tracks (NASDAQ:TRAX) with a Overweight and raises the price target from $48 to $65.